In a phase I clinical trial targeting CD19 and CD22 for the treatment of B-cell lymphoma, it was observed that the CD22 scFv triggered less cytokine secretion compared to the CD19 scFv, suggesting potential differences in the efficacy of CAR-T cells against different targets [19]. Here, CD19 is linked to B-cell non-Hodgkin lymphoma.